技术创新
Search documents
韩国总统访华经济代表团成员接受《环球时报》专访:“中国是我们的核心战略市场”
Huan Qiu Shi Bao· 2026-01-08 22:40
展望未来,李焕铁告诉记者,他们已制订在昆山扩大投资、扩建厂房的计划,"预计2027年起实现大规模销售,目标是在中国市场达成60亿元人民 币销售额,并推动中国法人独立上市。"除此之外,这位企业家说,爱恩斯还将在昆山开展韩中联合研发,根据中国患者的临床需求迭代产品,同 时构建韩中医生技术交流平台,让手术技术、治疗方法在深度交流中碰撞出更多火花。 【环球时报报道 记者 陈子帅】2026年伊始,中韩经贸交流热潮涌动。200余位韩国企业家组成的经济代表团随总统赴华,开启一场承载着深度合 作期许的经贸之旅。这是韩国时隔6年组织的最大规模对华经济访问团,在华期间,韩方企业家密集参与各类高端论坛,同中国企业围绕合作与技 术创新等议题深入交流、碰撞思路。接受《环球时报》记者采访的韩国企业家代表直言,代表团规模如此之大,释放一种明确信号——"韩国企业 将中国视为核心战略市场,希望通过与中国深度合作,共同发掘新的增长机遇。" " 这里是我创业路上不可或缺的土壤 " "我对中国的产业生态、市场活力有着直观的感受,这里早已是我创业路上不可或缺的土壤。"韩国熙恩斯公司创始人安重贤在接受《环球时报》 记者采访时,首先强调了他和中国密不可分 ...
高新区狮山商务创新区新添省级企业技术中心
Xin Hua Ri Bao· 2026-01-08 21:40
Core Insights - Three companies from Suzhou High-tech Zone Shishan Business Innovation District have been selected as provincial enterprise technology centers for 2025, which are crucial for building technological innovation systems and enhancing competitive market positions [1] Company Summaries - Suzhou Lianxun Instrument Co., Ltd. has achieved key technological breakthroughs in optical communication testing, power device testing, and semiconductor integrated circuit testing [1] - Suzhou Haipeng Technology Co., Ltd. focuses on distributed photovoltaic inverter products and smart energy management solutions, with products sold in over 70 countries across five continents [1] - Suzhou Gaiya Information Technology Co., Ltd. has developed core technologies for real-time parallel processing of massive data and dynamic scheduling algorithms for heterogeneous data, serving clients in 34 countries and regions with over 7 million employees using its services daily [1]
深耕高电压检测技术 助力新型电力系统建设
Xin Lang Cai Jing· 2026-01-08 20:04
在全球能源转型加速、电力系统呈现高电压与大容量发展趋势的背景下,高电压检测设备已成为保障电 力系统安全稳定运行的重要支撑。自山东希波成立以来,总经理彭英便专注于这一关键领域,以科学管 理、持续创新和国际化视野带领公司成长为国内高电压检测设备的重要力量。 创业初期,彭英便确立了以技术创新驱动企业发展的战略理念。在她的引领下,山东希波逐步构建了覆 盖研发、生产、销售的全产业链体系。同时,通过设立上海希波电气科技有限公司,打造了总部与生产 基地协同发展的双核模式。这一布局不仅优化了资源配置,也形成了技术研发到市场开拓的高效闭环, 使公司能够快速响应国内外市场需求。 彭英高度重视核心技术积累和科研成果转化。她带领团队持续推进500kV及以下高电压检测设备的迭代 研发。2014年以来,她参与发明并推动了包括"10kV悬挂式试验终端""110kV高压电缆局放试验水终端 装置""高压电缆局部放电干式试验终端及应力锥"在内的二十余项专利技术,这些成果构成了企业的核 心竞争力,为我国电力装备制造提供了可靠的技术保障,也推动了高电压试验设备整体技术水平的提 升。 展望未来,彭英表示将继续带领希波团队坚守技术创新与服务初心,推动高 ...
盛帮股份:公司未来将继续坚持目前行业定位
Zheng Quan Ri Bao Wang· 2026-01-08 14:13
Core Viewpoint - The company, Shengbang Co., Ltd. (301233), aims to maintain its current industry positioning focused on rubber polymer material products while exploring technological and product applications in other industries to enhance innovation and technical capabilities [1] Group 1 - The company will continue to focus on rubber polymer material products as its core business [1] - There is an emphasis on driving technological innovation and product applications into other industries [1] - The company plans to enhance its technological innovation and reserves to improve overall capabilities [1] Group 2 - The company intends to deepen penetration into existing product application areas [1] - There is a commitment to improving product technical capabilities across different industries [1] - The company aims to diversify its product portfolio in various sectors [1]
航发动力:公司持续在航空发动机领域深耕技术创新和产业升级
Zheng Quan Ri Bao Zhi Sheng· 2026-01-08 13:43
Core Viewpoint - The company aims to become a world-class aviation engine enterprise, focusing on technological innovation and industrial upgrades in the aviation engine sector [1] Group 1 - The company adheres to the mission of strengthening the military and serving the country through technology [1] - The company is committed to continuously enhancing its market competitiveness and influence according to its development strategy [1]
金力永磁发盈喜,预期年度归母净利润6.6亿元-7.6亿元 同比增长127%-161%
Zhi Tong Cai Jing· 2026-01-08 13:10
Core Viewpoint - The company, Jinli Permanent Magnet (金力永磁), expects to achieve a net profit attributable to shareholders of RMB 660 million to RMB 760 million for the fiscal year ending December 31, 2025, representing a year-on-year growth of 127% to 161% [1] Group 1: Financial Performance - The anticipated net profit for 2025 is between RMB 660 million and RMB 760 million, indicating significant growth compared to the previous year [1] - Non-recurring gains and losses are expected to impact net profit by approximately RMB 80 million [1] Group 2: Business Strategy and Operations - The company emphasizes that "technological innovation is the lifeblood of the enterprise" and plans to increase investment in R&D to drive development [1] - The company achieved record high production and sales volumes, reinforcing its leading position in the global rare earth permanent magnet industry [1] - In response to intensified industry competition, the management adheres to a prudent and compliant operational approach while actively expanding the market [1] Group 3: Product Applications and Partnerships - The company's products are widely used in various sectors, including new energy vehicles, energy-efficient variable frequency air conditioners, wind power generation, robotics, industrial servo motors, 3C, low-altitude aircraft, and energy-saving elevators [1] - The company has established long-term stable partnerships with leading enterprises in various fields [1] - Small batch deliveries of products related to robotic motor rotors and low-altitude aircraft have already been made during the reporting period [1] Group 4: Financial Costs - The company incurred approximately RMB 110 million in expenses related to A-share and H-share equity incentives and H-share convertible bond issuance, which includes share-based payment and financial costs [1]
金力永磁(06680)发盈喜,预期年度归母净利润6.6亿元-7.6亿元 同比增长127%-161%
智通财经网· 2026-01-08 13:03
Group 1 - The company expects a net profit attributable to shareholders of RMB 660 million to RMB 760 million for the year ending December 31, 2025, representing a year-on-year growth of 127% to 161% [1] - The company emphasizes that "technological innovation is the lifeblood of the enterprise" and plans to increase investment in R&D to drive development [1] - The company achieved record high product output and sales, further solidifying its position as a leader in the global rare earth permanent magnet industry [1] Group 2 - In response to increasing industry competition, the management adheres to a prudent and compliant operational approach while actively expanding the market [1] - The company has established long-term stable partnerships with leading enterprises in various fields, including new energy vehicles, energy-efficient air conditioning, wind power generation, and robotics [1] - The company has begun small-scale deliveries of products in the fields of robotic motor rotors and low-altitude aircraft [1] Group 3 - The estimated impact of non-recurring gains and losses on net profit is approximately RMB 80 million [1] - Due to A-share and H-share equity incentives and the issuance of H-share convertible bonds, related share-based payment expenses and financial costs total approximately RMB 110 million [1]
雷军最新发声:7年7500万重奖
21世纪经济报道· 2026-01-08 10:58
雷军表示,2026年小米技术创新有望迎来全新的突破。"今年我们有希望在一款终端产品上实 现自研芯片、自研OS、自研AI大模型的'大会师',同时我们的机器人业务也会有新的进展。" 他表示,作为小米开年首件大事,本次千万技术大奖竞争创历年之最,吸引10大部门150余个 项目角逐,最终底层核心技术类项目成为最大赢家,覆盖芯片、手机、汽车、AI、材料等关键 领域。 其中,小米自研芯片玄戒O1斩获本次大奖最高荣誉,雷军盛赞"当之无愧",并鼓励团 队再接再厉推出更优作品。 雷军在发言中强调两大核心原则:一是技术立业是小米穿越周期的关键支撑,在坚守模式、场 景、产品创新优势的基础上,必须持续推进硬核技术创新;二是工程师思维是小米核心价值 观,公司将为优秀人才搭建顶尖平台,持续提升工程师的获得感与幸福感。据披露,过去五年 小米已超额完成1000亿研发投入承诺,实际投入达1050亿元,当前研发人员总数超24000人, 本次获奖成果均为前期持续投入的重要产出。 面向2026年,雷军透露小米技术创新将迎来关键突破,有望在一款终端产品上实现自研芯片、 自研OS、自研AI大模型的"大会师",机器人业务也将有新进展。 作者丨雷晨 编辑丨 ...
雪迪龙,入选“北京市首台(套)重大技术装备目录”
仪器信息网· 2026-01-08 09:00
摘要 : 雪迪龙自主研发的"颗粒物全流程校验系统(SDL1006)",成功入选北京市发展和改革委员会《北 京市2025年第4批首台(套)重大技术装备目录》。 特别提示 微信机制调整,点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标,否则很可能无法看到我 们的推送。 近日, 雪迪龙自主研发的"颗粒物全流程校验系统(SDL1 0 0 6 ) ",成功入选北京市发展和改革 委员会《北京市2 0 2 5年第4批首台(套)重大技术装备目录》 ,技术创新能力与行业应用价值获 权威认可。 | 版 权 : 本 文 部 分 素 材 源 自 网 络 , 版 权 归 原 作 者 所 有 , 观 点 代 表 作 者 本 人 , 不 代 表 本 号 立 场 | 转 载 : 须 本 号 授 权 , 请 联 系 主 编 发 文 不 易 , 请 帮 小 编 点 下 "❤️" ↓ | 来 源 : 仪 器 信 息 网 | 作 者 : 小 苔 记 | 责 编 : 安 安 | 视 觉 : 长 艳 柱 子 点击文末" 阅读原文 "查看产品详情 ...
注射器行业报告:全球与中国市场现状及未来发展趋势
QYResearch· 2026-01-08 08:58
Core Viewpoint - The global syringe market is experiencing significant growth driven by increased demand for vaccinations and chronic disease management, with a notable shift towards high-value products such as safety syringes and pre-filled syringes [6][7][24]. Group 1: Current Industry Status - The global syringe market demand has surged, particularly during the COVID-19 pandemic, with a peak in 2021-2022. Post-pandemic, routine immunization and the rising number of chronic disease patients continue to sustain demand [6]. - Safety syringes and pre-filled syringes are becoming mainstream in the high-end market, with safety syringes having over 60% penetration in Europe and North America [7]. - The expansion of healthcare systems in emerging markets like India and Africa is further driving syringe demand [6]. Group 2: Industry Trends - Safety syringes are being widely promoted to reduce needle-stick injuries and cross-contamination risks, with organizations like WHO and FDA advocating for their use [12]. - The rise of smart syringes and digital products is noted, enhancing medication safety and patient self-management through features like dosage monitoring and injection records [13]. - Emerging markets are rapidly increasing their syringe consumption due to improved healthcare infrastructure and rising chronic disease management needs [14]. Group 3: Market Size and Forecast - The global syringe market is projected to reach $10.335 billion in sales by 2024, with an expected growth to $13.182 billion by 2031, reflecting a CAGR of 3.57% from 2025 to 2031 [18]. - The Chinese market is anticipated to grow from $1.117 billion in 2024 to $1.476 billion by 2031, increasing its global market share from 10.81% to 11.19% [18]. Group 4: Competitive Landscape - Major global syringe manufacturers include BD, Terumo, and Weigao Medical, with the top five companies holding a combined market share of 56.26% in 2024 [21]. - The syringe market is characterized by intense price competition, particularly in the disposable syringe segment, leading to low profit margins and overcapacity issues [25]. Group 5: Policy Analysis - Various policies are being implemented to promote the use of safety syringes and ensure quality control, including WHO guidelines and national health plans aimed at preventing cross-contamination during vaccinations [28][29].